Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
610.45
1 334.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Suven Pharmaceuticals Ltd
Gross Margin
Suven Pharmaceuticals Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | IN |
| Market Cap | 322.6B INR |
| Gross Margin |
61%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Gross Margin |
-3%
|
| Country | US |
| Market Cap | 749.7B USD |
| Gross Margin |
81%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Gross Margin |
56%
|
| Country | DK |
| Market Cap | 3.4T DKK |
| Gross Margin |
85%
|
| Country | US |
| Market Cap | 372B USD |
| Gross Margin |
69%
|
| Country | US |
| Market Cap | 257.3B USD |
| Gross Margin |
77%
|
| Country | CH |
| Market Cap | 200.4B CHF |
| Gross Margin |
73%
|
| Country | UK |
| Market Cap | 162.7B GBP |
| Gross Margin |
82%
|
| Country | CH |
| Market Cap | 179.9B CHF |
| Gross Margin |
75%
|
| Country | US |
| Market Cap | 146B USD |
| Gross Margin |
71%
|
Suven Pharmaceuticals Ltd
Glance View
Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Suven Pharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 61.4%.
You don't have any saved screeners yet
